Beta-blockers are often a lifelong medicine after a heart attack - but maybe they shouldn’t be

Key Points:

• Long-term use of beta-blockers after a heart attack is being reconsidered, with emerging research suggesting that stopping these medications after one or two years in stable patients may be safe and could reduce side effects and costs.
• The American Heart Association and American College of Cardiology updated guidelines in 2023, no longer recommending lifelong beta-blocker therapy for patients without a heart attack in the past year, reflecting evolving evidence.
• A recent study involving over 2,500 stable heart attack survivors in South Korea found no increased risk of death, recurrent heart attack, or heart failure hospitalization in patients who discontinued beta-blockers after at least one year compared to those who continued.
• While blood pressure and heart rate increased slightly after stopping beta-blockers, these remained within safe ranges, and the study emphasizes individualized decisions with shared doctor-patient discussions, especially for those experiencing side effects.
• The findings highlight a potential shift in clinical practice toward more cautious and selective long-term beta-blocker use, but further research is needed to confirm applicability across different populations and healthcare settings.